MACROGENICS, INC. Net Income
MACROGENICS, INC. (MGNX) reported Net Income of $19.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-14
- MACROGENICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $19.52M.
- MACROGENICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$36.77M.
- MACROGENICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $60.39M, a 17.31% increase year-over-year.
- MACROGENICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $16.82M, a 70.13% decline year-over-year.
- MACROGENICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$119.76M.
- MACROGENICS, INC. net income (loss) attributable to parent for fiscal 2021 was -$202.12M.
- MACROGENICS, INC. net income (loss) attributable to parent for fiscal 2020 was -$129.74M.
- MACROGENICS, INC. net income (loss) attributable to parent for fiscal 2019 was -$151.81M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.52M 10-Q · filed 2026-08-14 | -$17.26M 10-Q · filed 2026-08-14 | $43.13M derived: sum of 3 quarters · filed 2026-08-14 | $59.95M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$36.77M 10-Q · filed 2026-08-14 | $23.62M derived: sum of 2 quarters · filed 2026-08-14 | $40.44M derived: sum of 3 quarters · filed 2026-08-14 | $4.19M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $60.39M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-08 | $77.21M derived: sum of 2 quarters · filed 2026-04-08 | $40.96M derived: sum of 3 quarters · filed 2026-08-14 | -$74.62K DEF 14A · filed 2026-04-08 | -$74.62M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $16.82M 10-Q · filed 2025-11-12 | -$19.43M derived: sum of 2 quarters · filed 2026-08-14 | -$60.47M 10-Q · filed 2025-11-12 | -$8.99M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$36.25M 10-Q · filed 2026-08-14 | -$77.29M 10-Q · filed 2026-08-14 | -$25.81M derived: sum of 3 quarters · filed 2026-08-14 | $30.50M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$41.04M 10-Q · filed 2026-08-14 | $10.44M derived: sum of 2 quarters · filed 2026-08-14 | $66.75M derived: sum of 3 quarters · filed 2026-08-14 | $11.09M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2024-12-31 | $51.48M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-08 | $107.79M derived: sum of 2 quarters · filed 2026-04-08 | $52.12M derived: sum of 3 quarters · filed 2026-04-08 | -$66.97K DEF 14A · filed 2026-04-08 | -$66.97M 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $56.31M 10-Q · filed 2025-11-12 | $645.00K derived: sum of 2 quarters · filed 2025-11-12 | -$51.55M 10-Q · filed 2025-11-12 | -$88.57M derived: sum of 4 quarters · filed 2026-04-08 | |||
| 2024-06-30 | -$55.66M 10-Q · filed 2025-11-12 | -$107.85M 10-Q · filed 2025-08-14 | -$144.88M derived: sum of 3 quarters · filed 2026-04-08 | -$127.32M derived: sum of 4 quarters · filed 2026-04-08 | |||
| 2024-03-31 | -$52.19M 10-Q · filed 2025-11-12 | -$89.21M derived: sum of 2 quarters · filed 2026-04-08 | -$71.66M derived: sum of 3 quarters · filed 2026-04-08 | -$14.19M derived: sum of 4 quarters · filed 2026-04-08 | |||
| 2023-12-31 | -$37.02M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-08 | -$19.47M derived: sum of 2 quarters · filed 2026-04-08 | $38.00M derived: sum of 3 quarters · filed 2026-04-08 | -$9.06K DEF 14A · filed 2026-04-08 | -$9.06M 10-K · filed 2024-03-07 | ||
| 2023-09-30 | $17.55M 10-Q · filed 2024-11-05 | $75.02M derived: sum of 2 quarters · filed 2024-11-05 | $37.01M 10-Q · filed 2024-11-05 | $49.82M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-06-30 | $57.47M 10-Q · filed 2024-11-05 | $19.46M 10-Q · filed 2024-08-06 | $32.26M derived: sum of 3 quarters · filed 2025-03-20 | $7.45M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-03-31 | -$38.01M 10-Q · filed 2024-11-05 | -$25.21M derived: sum of 2 quarters · filed 2025-03-20 | -$50.02M derived: sum of 3 quarters · filed 2025-03-20 | -$91.32M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $12.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$12.01M derived: sum of 2 quarters · filed 2025-03-20 | -$53.31M derived: sum of 3 quarters · filed 2025-03-20 | -$119.76M 10-K · filed 2025-03-20 | |||
| 2022-09-30 | -$24.81M 10-Q · filed 2023-11-06 | -$66.12M derived: sum of 2 quarters · filed 2023-11-06 | -$132.56M 10-Q · filed 2023-11-06 | -$190.58M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-06-30 | -$41.30M 10-Q · filed 2023-11-06 | -$107.75M 10-Q · filed 2023-08-09 | -$165.77M derived: sum of 3 quarters · filed 2024-03-07 | -$218.66M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2022-03-31 | -$66.44M 10-Q · filed 2023-11-06 | -$124.47M derived: sum of 2 quarters · filed 2024-03-07 | -$177.35M derived: sum of 3 quarters · filed 2024-03-07 | -$217.29M derived: sum of 4 quarters · filed 2024-03-07 | |||
| 2021-12-31 | -$58.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$110.91M derived: sum of 2 quarters · filed 2024-03-07 | -$150.84M derived: sum of 3 quarters · filed 2024-03-07 | -$202.12M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | -$52.89M 10-Q · filed 2022-11-03 | -$92.82M derived: sum of 2 quarters · filed 2022-11-03 | -$144.09M 10-Q · filed 2022-11-03 | -$146.18M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-06-30 | -$39.94M 10-Q · filed 2022-11-03 | -$91.21M 10-Q · filed 2022-08-08 | -$93.29M derived: sum of 3 quarters · filed 2023-03-15 | -$129.34M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2021-03-31 | -$51.27M 10-Q · filed 2022-11-03 | -$53.36M derived: sum of 2 quarters · filed 2023-03-15 | -$89.40M derived: sum of 3 quarters · filed 2023-03-15 | -$136.29M derived: sum of 4 quarters · filed 2023-03-15 | |||
| 2020-12-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$38.13M derived: sum of 2 quarters · filed 2023-03-15 | -$85.02M derived: sum of 3 quarters · filed 2023-03-15 | -$129.74M 10-K · filed 2023-03-15 | |||
| 2020-09-30 | -$36.04M 10-Q · filed 2021-11-02 | -$82.93M derived: sum of 2 quarters · filed 2021-11-02 | -$127.65M 10-Q · filed 2021-11-02 | -$158.05M derived: sum of 4 quarters · filed 2021-11-02 | |||
| 2020-06-30 | -$46.88M 10-Q · filed 2021-11-02 | -$91.61M 10-Q · filed 2021-07-29 | -$122.00M derived: sum of 3 quarters · filed 2021-11-02 | -$166.64M derived: sum of 4 quarters · filed 2021-11-02 | |||
| 2020-03-31 | -$44.72M 10-Q · filed 2021-11-02 | -$75.12M derived: sum of 2 quarters · filed 2021-11-02 | -$119.75M derived: sum of 3 quarters · filed 2021-11-02 | -$151.52M derived: sum of 4 quarters · filed 2021-11-02 | |||
| 2019-12-31 | -$30.40M 10-K · filed 2020-02-25 | -$75.03M derived: sum of 2 quarters · filed 2020-11-04 | -$106.79M derived: sum of 3 quarters · filed 2020-11-04 | -$151.81M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$44.63M 10-Q · filed 2020-11-04 | -$76.40M derived: sum of 2 quarters · filed 2020-11-04 | -$121.42M 10-Q · filed 2020-11-04 | -$166.06M derived: sum of 4 quarters · filed 2020-11-04 | |||
| 2019-06-30 | -$31.77M 10-Q · filed 2020-11-04 | -$76.78M 10-Q · filed 2020-07-31 | -$121.43M derived: sum of 3 quarters · filed 2020-11-04 | -$155.46M derived: sum of 4 quarters · filed 2020-11-04 | |||
| 2019-03-31 | -$45.02M 10-Q · filed 2020-11-04 | -$89.66M derived: sum of 2 quarters · filed 2020-11-04 | -$123.69M derived: sum of 3 quarters · filed 2020-11-04 | -$166.93M derived: sum of 4 quarters · filed 2020-11-04 | |||
| 2018-12-31 | -$44.64M 10-K · filed 2020-02-25 | -$78.67M derived: sum of 2 quarters · filed 2020-02-25 | -$121.92M derived: sum of 3 quarters · filed 2020-02-25 | -$171.45M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$34.03M 10-K · filed 2020-02-25 | -$77.27M derived: sum of 2 quarters · filed 2020-02-25 | -$126.81M 10-Q · filed 2019-11-06 | -$21.08M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | -$43.24M 10-K · filed 2020-02-25 | -$92.78M 10-Q · filed 2019-07-31 | $12.95M derived: sum of 3 quarters · filed 2020-02-25 | -$34.10M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | -$49.54M 10-K · filed 2020-02-25 | $56.19M derived: sum of 2 quarters · filed 2020-02-25 | $9.15M derived: sum of 3 quarters · filed 2020-02-25 | -$31.51M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $105.73M 10-K · filed 2019-02-26 | $58.68M derived: sum of 2 quarters · filed 2019-02-26 | $18.03M derived: sum of 3 quarters · filed 2019-02-26 | -$19.63M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | -$47.04M 10-K · filed 2019-02-26 | -$87.70M derived: sum of 2 quarters · filed 2019-02-26 | -$125.35M 10-Q · filed 2018-11-07 | -$160.13M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | -$40.65M 10-K · filed 2019-02-26 | -$78.31M 10-Q · filed 2018-08-07 | -$113.09M derived: sum of 3 quarters · filed 2019-02-26 | -$146.94M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | -$37.66M 10-K · filed 2019-02-26 | -$72.44M derived: sum of 2 quarters · filed 2019-02-26 | -$106.28M derived: sum of 3 quarters · filed 2019-02-26 | -$65.82M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | -$34.78M 10-K · filed 2018-02-27 | -$68.63M derived: sum of 2 quarters · filed 2018-02-27 | -$28.16M derived: sum of 3 quarters · filed 2018-02-27 | -$58.53M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | -$33.85M 10-K · filed 2018-02-27 | $6.62M derived: sum of 2 quarters · filed 2018-02-27 | -$23.75M 10-Q · filed 2017-11-08 | -$52.20M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $40.46M 10-K · filed 2018-02-27 | $10.10M 10-Q · filed 2017-08-02 | -$18.35M derived: sum of 3 quarters · filed 2018-02-27 | -$33.79M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$30.36M 10-K · filed 2018-02-27 | -$58.81M derived: sum of 2 quarters · filed 2018-02-27 | -$74.26M derived: sum of 3 quarters · filed 2018-02-27 | -$95.63M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$28.45M 10-K · filed 2017-02-28 | -$43.89M derived: sum of 2 quarters · filed 2017-02-28 | -$65.27M derived: sum of 3 quarters · filed 2017-02-28 | -$20.14M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$15.44M 10-K · filed 2017-02-28 | -$36.82M derived: sum of 2 quarters · filed 2017-02-28 | $8.31M 10-Q · filed 2016-11-02 | -$10.71M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | -$21.38M 10-K · filed 2017-02-28 | $23.75M 10-Q · filed 2016-08-03 | $4.74M derived: sum of 3 quarters · filed 2017-02-28 | $807.00K derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $45.13M 10-K · filed 2017-02-28 | $26.11M derived: sum of 2 quarters · filed 2017-02-28 | $22.18M derived: sum of 3 quarters · filed 2017-02-28 | $9.92M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | -$19.02M 10-K · filed 2016-02-29 | -$22.95M derived: sum of 2 quarters · filed 2016-02-29 | -$35.20M derived: sum of 3 quarters · filed 2016-02-29 | -$38.31M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | -$3.93M 10-K · filed 2016-02-29 | -$16.19M derived: sum of 2 quarters · filed 2016-02-29 | -$19.30M 10-Q · filed 2015-11-04 | -$22.50M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$12.26M 10-K · filed 2016-02-29 | -$15.37M 10-Q · filed 2015-08-05 | -$18.57M derived: sum of 3 quarters · filed 2016-02-29 | -$11.97M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | -$3.11M 10-K · filed 2016-02-29 | -$3.11M 10-Q · filed 2014-05-06 | -$6.31M derived: sum of 2 quarters · filed 2016-02-29 | $291.00K derived: sum of 3 quarters · filed 2016-02-29 | -$3.00K derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | -$3.21M 10-K · filed 2015-03-03 | $3.40M derived: sum of 2 quarters · filed 2015-03-03 | $3.10M derived: sum of 3 quarters · filed 2015-03-03 | -$261.00K 10-K · filed 2016-02-29 | -$260.83K 10-K · filed 2014-03-20 | ||
| 2013-09-30 | $6.60M 10-K · filed 2015-03-03 | $6.60M 10-Q · filed 2013-11-12 | $6.31M derived: sum of 2 quarters · filed 2015-03-03 | $2.94M 10-Q · filed 2014-11-12 | $2.94M 10-Q · filed 2013-11-12 | $839.00K derived: sum of 4 quarters · filed 2015-03-03 | |
| 2013-06-30 | -$294.00K 10-K · filed 2015-03-03 | -$3.66M 10-Q · filed 2014-08-05 | -$5.76M derived: sum of 3 quarters · filed 2015-03-03 | -$3.16M derived: sum of 4 quarters · filed 2015-03-03 | |||
| 2013-03-31 | -$3.37M 10-K · filed 2015-03-03 | -$5.47M derived: sum of 2 quarters · filed 2015-03-03 | -$2.87M derived: sum of 3 quarters · filed 2015-03-03 | $676.00K derived: sum of 4 quarters · filed 2015-03-03 | |||
| 2012-12-31 | -$2.10M 10-K · filed 2014-03-20 | $496.00K derived: sum of 2 quarters · filed 2014-03-20 | $4.04M derived: sum of 3 quarters · filed 2014-03-20 | $8.36M 10-K · filed 2015-03-03 | $8.36M 10-K · filed 2014-03-20 | ||
| 2012-09-30 | $2.60M 10-K · filed 2014-03-20 | $2.60M 10-Q · filed 2013-11-12 | $6.15M derived: sum of 2 quarters · filed 2014-03-20 | $10.47M 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | $3.55M 10-K · filed 2014-03-20 | $7.87M derived: sum of 2 quarters · filed 2014-03-20 | |||||
| 2012-03-31 | $4.32M 10-K · filed 2014-03-20 | ||||||
| 2011-12-31 | $6.72M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |